Article
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.
The Lancet. Oncology - 1 Jun 2011
Bonnefoi Hervé, Piccart Martine, Bogaerts Jan, Mauriac Louis, Fumoleau Pierre, Brain Etienne, Petit Thierry, Rouanet Philippe, Jassem Jacek, Blot Emmanuel, Zaman Khalil, Cufer Tanja, Lortholary Alain, Lidbrink Elisabet, André Sylvie, Litière Saskia, Lago Lissandra Dal, Becette Véronique, Cameron David A, Bergh Jonas, Iggo Richard
Abstract excerpt
BACKGROUND: TP53 has a crucial role in the DNA damage response. We therefore tested the hypothesis that taxanes confer a greater advantage than do anthracyclines on breast cancers with mutated TP53 than in those with wild-type TP53. METHODS: In an open-label, phase 3 study, women (age <71 years) with locally advanced, inflammatory, or large operable breast cancers were randomly assigned in a 1:1 ratio to either a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.